flecainide has been researched along with Coronary Artery Disease in 5 studies
Flecainide: A potent anti-arrhythmia agent, effective in a wide range of ventricular and atrial ARRHYTHMIAS and TACHYCARDIAS.
flecainide : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 2,5-bis(2,2,2-trifluoroethoxy)benzoic acid with the primary amino group of piperidin-2-ylmethylamine. An antiarrhythmic agent used (in the form of its acetate salt) to prevent and treat tachyarrhythmia (abnormal fast rhythm of the heart).
Coronary Artery Disease: Pathological processes of CORONARY ARTERIES that may derive from a congenital abnormality, atherosclerotic, or non-atherosclerotic cause.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Flecainide is a class IC antiarrhythmic drug that is contraindicated in patients who have a history of myocardial infarction, but its effect on mortality and risk of proarrhythmia in patients with stable obstructive and nonobstructive epicardial coronary artery disease (CAD) has not been assessed." | 8.02 | Use of Flecainide in Stable Coronary Artery Disease: An Analysis of Its Safety in Both Nonobstructive and Obstructive Coronary Artery Disease. ( Agasthi, P; Ashraf, H; Ko, NK; Ladia, V; Mulpuru, SK; O'Herlihy, F; Prendiville, T; Pujari, SH; Scott, L; Sorajja, D, 2021) |
| "Flecainide is a class IC antiarrhythmic drug that is contraindicated in patients who have a history of myocardial infarction, but its effect on mortality and risk of proarrhythmia in patients with stable obstructive and nonobstructive epicardial coronary artery disease (CAD) has not been assessed." | 4.02 | Use of Flecainide in Stable Coronary Artery Disease: An Analysis of Its Safety in Both Nonobstructive and Obstructive Coronary Artery Disease. ( Agasthi, P; Ashraf, H; Ko, NK; Ladia, V; Mulpuru, SK; O'Herlihy, F; Prendiville, T; Pujari, SH; Scott, L; Sorajja, D, 2021) |
| "Flecainide is a useful antiarrhythmic for atrial fibrillation (AF)." | 1.62 | Absent or Mild Coronary Calcium Predicts Low-Risk Stress Test Results and Outcomes in Patients Considered for Flecainide Therapy. ( Anderson, JL; Bunch, TJ; Cutler, MJ; Knight, S; Knowlton, KU; Le, VT; Mason, S; May, HT; McCubrey, RO; Min, DB; Muhlestein, JB, 2021) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 5 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Burnham, TS | 1 |
| May, HT | 2 |
| Bair, TL | 1 |
| Anderson, JA | 1 |
| Crandall, BG | 1 |
| Cutler, MJ | 2 |
| Day, JD | 1 |
| Freedman, RA | 1 |
| Knowlton, KU | 2 |
| Muhlestein, JB | 2 |
| Navaravong, L | 1 |
| Ranjan, RA | 1 |
| Steinberg, BA | 1 |
| Bunch, TJ | 2 |
| Anderson, JL | 1 |
| Knight, S | 1 |
| McCubrey, RO | 1 |
| Mason, S | 1 |
| Min, DB | 1 |
| Le, VT | 1 |
| Reiffel, JA | 1 |
| Kiani, S | 1 |
| Sayegh, MN | 1 |
| Ibrahim, R | 1 |
| Bhatia, NK | 1 |
| Merchant, FM | 1 |
| Shah, AD | 1 |
| Westerman, SB | 1 |
| De Lurgio, DB | 1 |
| Patel, AM | 1 |
| Thompkins, CM | 1 |
| Leon, AR | 1 |
| Lloyd, MS | 1 |
| El-Chami, MF | 1 |
| Ashraf, H | 1 |
| Ko, NK | 1 |
| Ladia, V | 1 |
| Agasthi, P | 1 |
| Prendiville, T | 1 |
| O'Herlihy, F | 1 |
| Pujari, SH | 1 |
| Mulpuru, SK | 1 |
| Scott, L | 1 |
| Sorajja, D | 1 |
5 other studies available for flecainide and Coronary Artery Disease
| Article | Year |
|---|---|
Long-term outcomes in patients treated with flecainide for atrial fibrillation with stable coronary artery disease.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Coronary Artery Disease; Flecainide; Humans; Prospectiv | 2022 |
Absent or Mild Coronary Calcium Predicts Low-Risk Stress Test Results and Outcomes in Patients Considered for Flecainide Therapy.
Topics: Aged; Anti-Arrhythmia Agents; Calcium; Coronary Angiography; Coronary Artery Disease; Exercise Test; | 2021 |
The safety of flecainide for atrial fibrillation in patients with stable coronary artery disease - Fact or fallacy.
Topics: Atrial Fibrillation; Coronary Artery Disease; Flecainide; Heart Atria; Humans | 2022 |
The Feasibility and Safety of Flecainide Use Among Patients With Varying Degrees of Coronary Disease.
Topics: Coronary Artery Disease; Feasibility Studies; Flecainide; Humans; Retrospective Studies; Sotalol; Ta | 2023 |
Use of Flecainide in Stable Coronary Artery Disease: An Analysis of Its Safety in Both Nonobstructive and Obstructive Coronary Artery Disease.
Topics: Coronary Artery Disease; Flecainide; Humans; Retrospective Studies | 2021 |